Chimeric Therapeutics (ASX: CHM) is developing ground-breaking CAR-T cell therapies for solid tumors based on scientific research conducted by leading US CAR-T experts. It is currently in a phase 1 clinical trial for its lead asset, CLTX-CAR T, a novel and promising CAR T therapy for the treatment of patients with Glioblastoma. It also has a second asset in its portfolio, having an exclusive license to a novel CAR T for solid tumors from renowned cell therapy institution, the University of Pennsylvania.
